Research programme: obesity therapeutics - Akron Molecules

Drug Profile

Research programme: obesity therapeutics - Akron Molecules

Alternative Names: AKR-101

Latest Information Update: 17 Oct 2013

Price : $50

At a glance

  • Originator Akron Molecules
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Obesity

Most Recent Events

  • 16 Oct 2013 Preclinical trials in Obesity in Austria (unspecified route) before October 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top